Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Bai, Yalai ^a   Cheng, Huan ^a   Bordeaux, Jennifer ^a   Neumeister, Veronique ^a   Kumar, Sudha ^a   Rimm, David L ^a   Stern, David F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHO HER2 PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CORE NEEDLE BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; QUANTITATIVE IMMUNOFLUORESCENCE METHOD; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; MIDDLE AGED; PHOSPHORYLATION; RETROSPECTIVE STUDIES; SPECIMEN HANDLING; TISSUE ARRAY ANALYSIS;

EID: 84896732364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079901     Document Type: Article

References (39)

1. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145. (Pubitemid 350003059)
2. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, et al. (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24: 3032-3038. (Pubitemid 46638937)
3. Neumeister VM, Anagnostou V, Siddiqui S, England AM, Zarrella ER, et al. (2012) Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst 104: 1815-1824.
4. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R (2012) The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol 25: 1098-1105.
5. Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, et al. (2009) Delay to formalin fixation effect on breast biomarkers. Mod Pathol 22: 1457-1467.
6. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, et al. (2005) Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 11: 4338-4340. (Pubitemid 40825621)
7. Bai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, et al. (2011) Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest 91: 1253-1261.
8. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D, 2nd, et al. (2005) Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23: 1152-1160. (Pubitemid 46202271)
9. Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, et al. (2007) Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 25: 5418-5425. (Pubitemid 350232218)
10. Li X, Deavers MT, Guo M, Liu P, Gong Y, et al. (2013) The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer. Mod Pathol 26: 71-78.
11. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL (2005) Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 97: 1808-1815. (Pubitemid 43033901)
12. Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, et al. (2011) Standardization of estrogen receptor measurement in breast cancer suggests false- negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 29: 2978-2984.
13. Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8: 1323-1327. (Pubitemid 35373567)
14. Moeder CB, Giltnane JM, Moulis SP, Rimm DL (2009) Quantitative, fluorescence- based in-situ assessment of protein expression. Methods Mol Biol 520: 163-175.
15. DiGiovanna MP, Stern DF (1995) Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer research 55: 1946-1955.
16. DiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD, et al. (1998) Active signaling by Neu in transgenic mice. Oncogene 17: 1877-1884. (Pubitemid 28482791)
17. Ginestier C, Adelaide J, Goncalves A, Repellini L, Sircoulomb F, et al. (2007) ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 26: 7163-7169. (Pubitemid 350059680)
18. Pirrelli M, Caruso ML, Di Maggio M, Armentano R, Valentini AM (2013) Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci 58: 397-404.
19. Connor CS, Tawfik OW, Joyce AJ, Davis MK, Mayo MS, et al. (2002) A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg 184: 322-324. (Pubitemid 35287351)
20. Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, et al. (2010) HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens. BMC Cancer 10: 534.
21. Lebeau A, Turzynski A, Braun S, Behrhof W, Fleige B, et al. (2010) Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle Biopsies. Journal of Clinical Oncology 28: 3264-3270.
22. Nakamura R, Yamamoto N, Onai Y, Watanabe Y, Kawana H, et al. (2012) Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients. Breast Cancer.
23. Hanna W, Nofech-Mozes S, Kahn HJ (2007) Intratumoral heterogeneity of HER2/neu in breast cancer-a rare event. Breast J 13: 122-129. (Pubitemid 46280606)
24. Shin SJ, Hyjek E, Early E, Knowles DM (2006) Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray. Int J Surg Pathol 14: 279-284. (Pubitemid 44545764)
25. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, et al. (2005) Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58: 172-177. (Pubitemid 40193803)
26. Brunelli M, Manfrin E, Martignoni G, Miller K, Remo A, et al. (2009) Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 131: 678-682.
27. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, et al. (2008) Hypoxia- inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 110: 465-475. (Pubitemid 351962589)
28. Pertschuk LP, Axiotis CA, Feldman JG, Kim YD, Karavattayhayyil SJ, et al. (1999) Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems. Breast J 5: 369-374.
29. Glockner S, Buurman H, Kleeberger W, Lehmann U, Kreipe H (2002) Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 82: 1419-1426. (Pubitemid 35191545)
30. Cross SS, Start RD, Smith JH (1990) Does delay in fixation affect the number of mitotic figures in processed tissue? J Clin Pathol 43: 597-599. (Pubitemid 20203722)
31. Sliwkowski MX (2003) Ready to partner. Nat Struct Biol 10: 158-159.
32. Allen J, Winterford C, Axelsen RA, Gobe GC (1992) Effects of hypoxia on morphological and biochemical characteristics of renal epithelial cell and tubule cultures. Ren Fail 14: 453-460.
33. Hudelist G, Kostler WJ, Attems J, Czerwenka K, Muller R, et al. (2003) Her-2/neu- triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 89: 983-991. (Pubitemid 37239199)
34. Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, et al. (2012) PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23: 2034-2042.
35. Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, et al. (2005) Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest 23: 483-487. (Pubitemid 41463863)
36. Paik S, Kim C, Wolmark N (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358: 1409-1411. (Pubitemid 351468442)
37. Thor AD, Liu S, Edgerton S, Moore D, 2nd, Kasowitz KM, et al. (2000) Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 18: 3230-3239.
38. Taniyama K, Ishida K, Toda T, Motoshita J, Kuraoka K, et al. (2008) Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas. Breast Cancer 15: 231-240.
39. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, et al. (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919. (Pubitemid 47294799)